TA-316

• Description:

  TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells[1][2].

• Product Name Alternative:

  Megakaryocytes/platelets inducing agent

• UNSPSC:

  12352005

• Hazard Statement:

  H303, H315, H319, H335

• Target:

  Cyclin G-associated Kinase (GAK)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Megakaryocytes-platelets_inducing_agent.html

• Purity:

  99.50

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C (C1=CC=C (C (NCC2=CC=C (C (NCCO) =O) C=C2) =O) S1) N/N=C (C3=CSC (C4=CC=C (Br) C=C4) =C3O) \C

• Molecular Formula:

  C28H25BrN4O5S2

• Molecular Weight:

  641.56

• Precautions:

  H303, H315, H319, H335

• References & Citations:

  [1]METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS.WO2013051625A1.|[2]Aihara A, et al. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells. Blood Adv. 2017;1 (7) :468-476. Published 2017 Feb 28.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1429321-13-0